touchHAEMATOLOGY touchHAEMATOLOGY
Start activity

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

How do you most frequently assess the impact of ITP on your patientsā€™ quality of life (QoL)?

Submit your answer to see the results

PRO tools
   
Enquire verbally
   
Other
   
I donā€™t assess QoL
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following emerging treatments for ITP do you feel most familiar with in terms of available clinical data?

Submit your answer to see the results

Ianalumab
   
Rilzabrutinib
   
Sovleplenib
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the approved TPO-RAs do you most commonly use first in your adult patients with ITP?

Submit your answer to see the results

Avatrombopag
   
Romiplostim
   
Eltrombopag
   
All used equally
   
 
Videos Take CE/CME Test
Thrombocytopenia, Rare Diseases CE/CME accredited

touchPANEL DISCUSSION
A visually engaging discussion designed to emulate a ā€˜liveā€™ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity. Close

What’s new in primary ITP? Key updates from ASH 2024

  • Select in the video player controls bar to choose subtitle language. Subtitles available in English, Simplified Chinese, French, German, Italian, Japanese, Spanish.
  • A practice aid is available for this activity in the Toolkit
  • Downloads including slides are available for this activity in the Toolkit
Learning Objectives

After watching this activity, participants should be better able to:

  • Review current management practices for ITP
  • Discuss how the latest data for emerging therapies are likely to impact future clinical practice
  • Consider the impact of ITP on patientsā€™ lives
Overview

In this activity, three expert haematologists discuss real-world management practices for primary immune thrombocytopenia (ITP), emerging targeted treatments and the burden of ITP on patientsā€™ lives. The faculty share their insights and review some of the latest data from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.

This activity is jointly provided by USF Health and touchIME. read more

Target Audience

This activity has been designed to meet the educational needs of haematologists and haemato-oncologists involved in the management of patients with ITP.

USF Accreditation

Disclosures

USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

Faculty

Dr Hanny Al-Samkari discloses: Consultant fees from Agios, Alnylam, Alpine, Amgen, Argenx, Novartis, Pharmacosmos and Sobi. Grants/research support from Agios, Amgen, Novartis, Sobi and Vaderis.

Dr Drew Provan discloses: Consultant fees from Argenx, Argobio, Candidrx, Dexcel, MedImmune, Nuvig, Ono, Sobi and UCB. Speakerā€™s bureau fees from Amgen, Grifols, Novartis and Sobi.

Dr Barbara Skopec discloses: Advisory board or panel fees from AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Sobi and Takeda. Consultant fees from AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Sobi and Takeda. Speakerā€™s bureau fees from AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Sobi and Takeda.

Content reviewer

Danielle Walker, DNP, APRN, AGNP-C has no financial interests/relationships or affiliations in relation to this activity.

Touch Medical Contributors

Katrina Lester has no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

Requirements for Successful Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact cpdsupport@usf.edu

Accreditations

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 0.75Ā AMA PRA Category 1 CreditTM.Ā  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Advanced Practice Providers

Physician Assistants may claim a maximum of 0.75Ā Category 1Ā credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Date of original release: 30 January 2025. Date credits expire: 30 January 2028.

If you have any questions regarding credit, please contact cpdsupport@usf.edu

EBACĀ® Accreditation

touchIME is an EBACĀ® accredited provider since 2023.

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBACĀ®) for 1 hour of effective education time.

EBACĀ® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBACĀ®) and the American Medical Association, physicians may convert EBACĀ® External CME credits to AMA PRA Category 1 Creditsā„¢. Information on the process to convert EBACĀ® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Creditā„¢.

EBACĀ® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

Faculty Disclosure Statement / Conflict of Interest Policy

In compliance with EBACĀ® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.

Requirements for Successful Completion

Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBACĀ® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBACĀ® CE credit certificate. EBACĀ® grants 1 CE credit for every hour of education completed.

Time to complete: 55 minutes

If you have any questions regarding the EBACĀ® credits, please contact accreditation@touchime.orgĀ 

This activity is CE/CME accredited

To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

Claim Credit
  • Select in the video player controls bar to choose subtitle language. Subtitles available in English, Simplified Chinese, French, German, Italian, Japanese, Spanish.
  • A practice aid is available for this activity in the Toolkit
  • Downloads including slides are available for this activity in the Toolkit

Topics covered in this activity

Thrombocytopenia / Rare Diseases
REGISTER NOW FOR FREE ACCESS TO
  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
Claim Credit
touchPANEL DISCUSSION
What’s new in primary ITP? Key updates from ASH 2024
0.75 CE/CME credit

Question 1/5
Why are TPO-RAs a favoured second-line treatment option for patients with ITP?

ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.

TPO-RAs have provided excellent responses of >60% in patients with ITP,1 and in some regions these agents are often recommended as the first option for second-line treatment for patients with ITP.2 Switching from one TPO-RA to another can have a positive effect on response and tolerability. Reasons for switching include inefficacy, side effects and patient preference.1

Abbreviations

ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.

References

  1. Provan D, et al. Blood Adv. 2019;3:3780ā€“817.
  2. Mingot Castellano ME, et al. J Clin Med. 2023;12:6422.
Question 2/5
Your 79-year-old patient was diagnosed with ITP 7 months ago. They initially responded to a short course of oral prednisolone, but relapsed after discontinuation. You are discussing second-line treatment options and they express concern regarding having to remember to take medication daily. What would you do?

ITP, immune thrombocytopenia.

Romiplostim is administered as a once-weekly subcutaneous injection,1,2 either at a clinic or at home.3 Eltrombopag and fostamatinib are oral medications with once daily and twice daily dosing, respectively,1,2 which may not be ideal for patients who may forget to take daily medication. A splenectomy is not recommended in patients with ITP for <12 months due to the potential of spontaneous remission.4,5

Abbreviation

ITP, immune thrombocytopenia.

References

  1. FDA. Prescribing information. Available at: www.accessdata.fda.gov/scripts/cder/daf/index.cfm (accessed 10 January 2025).
  2. EMA. Summary of product characteristics. Available at: www.medicines.org.uk/emc (accessed 10 January 2025).
  3. Gerard Jansen AJ, et al. Hematology. 2023;28:2267942.
  4. Neunert C, et al. Blood Adv. 2019:3:3829ā€“66.
  5. Provan D, et al. Blood Adv. 2019;3:3780ā€“817.
Question 3/5
Your adult patient with chronic ITP is on their third line of treatment and is receiving a TPO-RA. Their recent platelet counts range between 15ā€“25 x 109/L and they report feeling extremely fatigued. You are discussing potential enrolment in a clinical trial with rilzabrutinib and your patient enquires about expected outcomes. Based on data from LUNA 3 presented at ASH 2024, what would you tell them?

ASH, American Society of Hematology; DR, durable platelet response; ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.

Data from LUNA 3, investigating the efficacy and safety of rilzabrutinib (n=133) vs placebo (n=69) in patients with primary persistent/chronic ITP, were presented at ASH 2024 (data cut-off 14 March 2024). The primary endpoint was met, with 23% of the rilzabrutinib arm vs 0% of the placebo arm demonstrating a DR (p<0.0001). DR was defined as a platelet count ā‰„50 x 109/L for at least two-thirds of ā‰„8 of the last 12 weeks of the 24-week blinded treatment period in the absence of rescue medication.1 Patients receiving rilzabrutinib demonstrated significant improvement in physical fatigue vs placebo at week 13 (p=0.0114) and 25 (p=0.0003).2

Abbreviations

ASH, American Society of Hematology; DR, durable platelet response; ITP, immune thrombocytopenia.

References

  1. Kuter DJ, et al. Presented at: 66th ASH Annual Meeting and Exposition, 7ā€“10 December 2024, San Diego, CA, USA. Abstr 5.
  2. Ghanima W, et al. Presented at: 66th ASH Annual Meeting and Exposition, 7ā€“10 December 2024, San Diego, CA, USA. Abstr 2552.
Question 4/5
Your adult patient with primary chronic ITP, previously treated with corticosteroids and a TPO-RA, is enrolled in a clinical trial of sovleplenib. Based on safety data presented at ASH 2024 for the ESLIM-01 extension trial with sovleplenib, what would you do to identify the most frequent potential grade ā‰„3 TRAEs?

ASH, American Society of Hematology; BP, blood pressure; ECG, electrocardiogram; ITP, immune thrombocytopenia; LFT, liver function test; TPO-RA, thrombopoietin receptor agonist; TRAE, treatment-related adverse event.

The long-term safety and efficacy of sovleplenib in patients with chronic primary ITP in China is being studied in the ESLIM-01 extension stage. Interim analysis (data cut-off 31 January 2024) of safety data demonstrated that the three most common grade ā‰„3 TRAEs (>1%) in all patients receiving sovleplenib (N=179) were increased ALT (2.2%), decreased neutrophil count (1.7%) and increased GGT (1.7%).Ā 

Abbreviations

ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; ITP, immune thrombocytopenia; TRAE, treatment-related adverse event.

Reference

Hu Y, et al. Presented at: 66th ASH Annual Meeting and Exposition, 7ā€“10 December 2024, San Diego, CA, USA. Abstr 2558.

Question 5/5
What percentage of patients with chronic/newly diagnosed ITP are affected by symptomatic bleeding?

ITP, immune thrombocytopenia.

Symptomatic bleeding affects 60ā€“70% of patients with chronic ITP and 70ā€“80% of patients with newly diagnosed ITP.Ā 

Abbreviation

ITP, immune thrombocytopenia.Ā 

Reference

Matzdorff A, et al. Oncol Res Treat. 2018;41:1ā€“30.

Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup